Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis

Journal of the Neurological Sciences

Volumn 323, Issue 1-2, 2012, Pages 104-112

  Prosperini, Luca ^a   Giannì, Costanza ^a   Barletta, Valeria ^a   Mancinelli, Chiara ^a   Fubelli, Federica ^a   Borriello, Giovanna ^a   Pozzilli, Carlo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti natalizumab antibodies; Freedom from disease activity; Multiple sclerosis; Natalizumab; Observational study; Response to therapy

Indexed keywords

NATALIZUMAB;

ADOLESCENT; ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ACTIVITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; CELL MIGRATION INHIBITION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PRODUCT SURVEILLANCE, POSTMARKETING; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867849114     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.08.027     Document Type: Article

References (35)

1. T.A. Yednock, C. Cannon, C. Vandevert, E.G. Goldbach, G. Shaw, and D.K. Ellis Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin Nature 356 1992 63 66
2. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
3. R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, and E.W. Radue Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 2006 911 923
4. E. Havrdova, S. Galetta, M. Hutchinson, D. Stefoski, D. Bates, and C.H. Polman Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study Lancet Neurol 8 2009 254 260
5. A.B. Oturai, N. Koch-Henriksen, T. Petersen, P.E. Jensen, F. Sellebjerg, and P.S. Sorensen Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study Eur J Neurol 16 2009 420 423
6. N. Putzki, O. Yaldizli, M. Mäurer, S. Cursiefen, S. Kuckert, and C. Klawe Efficacy of natalizumab in second-line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries Eur J Neurol 17 2010 31 37
7. S. Belachew, R. Phan-Ba, E. Bartholomé, V. Delvaux, I. Hansen, and P. Calay Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis Eur J Neurol 18 2011 240 245
8. L. Prosperini, G. Borriello, F. Fubelli, F. Marinelli, and C. Pozzilli Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome Neurol Sci 31 Suppl. 3 2011 303 307
9. F. Sangalli, L. Moiola, S. Bucello, P. Anovazzi, A. Rizzo, and M. Radaelli Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study Neurol Sci 31 Suppl. 3 2011 299 302
10. A. Melin, O. Outteryck, N. Collongues, H. Zephir, M.C. Fleury, and F. Blanc Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis J Neurol 2011 10.1007/s00415-011-6339-8
11. L. Prosperini, C. Giannì, L. Leonardi, L. De Giglio, G. Borriello, and S. Galgani Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis Mult Scler 18 2012 58 65
12. R. Lanzillo, M. Quarantelli, S. Bonavita, G. Ventrella, G. Lus, and G. Vacca Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study Acta Neurol Scand 2011 10.1111/j.1600-0404.2011.01622.x
13. D. Bates, and E. Bartholomé Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity J Neurol Neurosurg Psychiatry 83 2012 55 60
14. M. Hutchinson, L. Kappos, P.A. Calabresi, C. Confavreux, C. Giovannoni, and S.L. Galetta The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL J Neurol 256 2009 405 415
15. E. Havrdova, S. Galetta, D. Stefoski, and G. Comi Freedom from disease activity in multiple sclerosis Neurology 74 Suppl. 3 2010 S3 S7
16. C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, and L. Kappos Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria Ann Neurol 58 2005 840 846
17. G.L. Mancardi, G. Tedeschi, M.P. Amato, R. D'Alessandro, F. Drago, and C. Milanese Three years of experience: the Italian registry and safety data update Neurol Sci 31 Suppl. 3 2011 295 297
18. J.F. Kurtzke Rating neurological impairment in Multiple Sclerosis: an Expanded Disability Status Scale (EDSS) Neurology 33 1983 1444 1452
19. M. Filippi, M.A. Rocca, D.L. Arnold, R. Bakshi, F. Barkhof, and N. De Stefano EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis Eur J Neurol 13 2006 313 325
20. P.A. Calabresi, G. Giovannoni, C. Confavreux, S.L. Galetta, E. Havrdova, and M. Hutchinson The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL Neurology 69 2007 1391 1403
21. L. Breiman, J. Friedman, and C.J. Ohlsen Classification and regression trees 1984 Chapman and Hall London, UK
22. R.A. Rudick, J.C. Lee, J. Simon, R.M. Ransohoff, and E. Fisher Defining interferon beta response status in multiple sclerosis patients Ann Neurol 56 2004 548 555
23. V. Tomassini, A. Paolillo, P. Russo, E. Giugni, L. Prosperini, and C. Gasperini Predictors of long-term clinical response to Interferon beta therapy in relapsing Multiple Sclerosis J Neurol 253 2006 287 293
24. J. Rio, A. Rovira, M. Tintoré, E. Huerga, C. Nos, and N. Tellez Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients Mult Scler 14 2008 479 484
25. L. Durelli, P. Barbero, M. Bergui, E. Versino, M.A. Bassano, and E. Verdun MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis J Neurol Neurosurg Psychiatry 79 2008 646 651
26. L. Prosperini, V. Gallo, N. Petsas, G. Borriello, and C. Pozzilli One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis Eur J Neurol 16 2009 1202 1209
27. C.M. Dalton, K.A. Miszkiel, G.J. Barker, D.G. MacManus, T.I. Pepple, and M. Panzara Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis J Neurol 251 2004 407 413
28. E. Havrdova, S. Galetta, D. Hutchinson, D. Stefoski, D. Bates, and C.H. Polman Demographic and baseline disease characteristics associated with freedom for disease activity in natalizumab-treated patients Mult Scler 16 Suppl. 1 2010 S320
29. H. Wiendl, S. Belachew, H. Butzkueven, L. Kappos, F. Pellegrini, and M. Trojano Assessment of the association between baseline characteristics and post-baseline relapses, disability progression, and improvement over time in the natalizumab observational program (TOP) in patients with multiple sclerosis Mult Scler 17 Suppl. 10 2011 S217
30. E. Portaccio, V. Zipoli, G. Siracusa, S. Sorbi, and M.P. Amato Response to interferon beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria Mult Scler 12 2006 281 286
31. R.A. Rudick, and C.H. Polman Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis Lancet Neurol 8 2009 545 559
32. C. Pozzilli, N. Petsas, and L. Prosperini MRI for monitoring response to preventive treatment in multiple sclerosis Expert Rev Neurother 9 2009 305 307
33. N.F. Blair, B.J. Brew, and J.P. Halpern Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance Neurology 78 2012 507 508
34. L. Gorelik, M. Lerner, S. Bixler, M. Crossman, B. Schlain, and K. Simon Anti-JC virus antibodies: implications for PML risk stratification Ann Neurol 68 2010 295 303
35. P.S. Sorensen, A. Bertolotto, G. Edan, G. Giovannoni, R. Gold, and E. Havrdova Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab Mult Scler 18 2012 143 152